title: The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy.
abstract: This case confirms the observation that urothelial carcinomas can secrete beta-hCG, and that beta-hCG can potentially be used as a marker of a patient's clinical response to treatment. Prospective studies are clearly warranted by these observations.
authors.affiliation: Yale-New Haven Hospital, New Haven, Connecticut, USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Malkhasyan
authors.affiliation: Division of Oncology, Department of Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
authors.forename: Hari A
authors.initials: HA
authors.lastname: Deshpande
authors.affiliation: Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
authors.forename: Adebowale J
authors.initials: AJ
authors.lastname: Adeniran
authors.affiliation: Department of Urology, Yale School of Medicine, New Haven, Connecticut, USA.
authors.forename: John W
authors.initials: JW
authors.lastname: Colberg
authors.affiliation: Division of Oncology, Department of Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Petrylak
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D018997:Chorionic Gonadotropin, beta Subunit, Human